The FDA Is Not Ready For Federal Preemption Of Lawsuits Involving Drugs And Medical Devices

Patient Lawsuits Against Pharmaceutical Companies For Drug Injuries Might Be Prohibited In U.S.

Issue: Should We Be Prohibited From Filing Product Liability Lawsuits Against Medical Companies

November 2009 Medical Journal Article Describes Large Ongoing Study About Safety Of YAZ
INAS-OC Study: Intended To Evaluate Risk Of Developing Cardiovascular Side Effects For Women Who Use YAZ (DRSP/EE 24d) (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2009 we first wrote about the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study), which is intended to evaluate the risk of developing cardiovascular side effects for women who use YAZ, a popular b

Drug Industry Document Archive (DIDA) Adds 15 More Pharma-Related Documents To Collection In Novembe
This Archive Contains Some "Secret" Documents Only Made Public In The Course Of Lawsuits Filed Against Pharmaceutical Companies (Posted by Tom Lamb at DrugInjuryWatch.com) Created and maintained by the University of California at San Francisco (UCSF), the Drug Industry Document Archive (DIDA) contains over 1500 documents, many of which were previously secret and only made public

Consumers Union’s Safe Patient Project Forum Webcast: “To Err Is Human, To Delay Is Deadly”
Marks 10th Anniversary Of IOM Study On Medical Errors And Raises Concerns About Lack Of Progress (Posted by Tom Lamb at DrugInjuryWatch.com) The Consumers Union’s Safe Patient Project (formerly Stop Hospital Infections) is holding a forum, “To Err Is Human, To Delay Is Deadly,” in Washington, DC, today

Anemia Drugs Procrit And Aranesp May Increase Twofold The Risk Of Potentially Fatal Blood Clots
Results From Large Long-Term Study Show Association Between These Erythropoiesis-Stimulating Agents And Venous Thromboembolism(Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2009 we learned that the results from the Trial to Reduce Cardiovascular Events with Aransep Treatment (TREAT) indicated that

Aranesp Associated With Increased Risk For Stroke In Patients With Diabetes And Chronic Kidney Disea
TREAT Study Revealed, Also, That This Amgen Anemia Drug Was No Better Than Placebo In Reducing Deaths Or Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) The anemia drug Aranesp (darbepoetin alfa) might cause an increased risk for stroke in patients with diabetes and chronic kidney disease, according to the results from the Trial to Reduce Cardiovascular Events with Aransep Treatment